These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 27226407

  • 1. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N, Kainz S, Petritsch W, Haas T, Feichtenschlager T, Novacek G, Eser A, Vogelsang H, Reinisch W, Papay P.
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [Abstract] [Full Text] [Related]

  • 2. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.
    Inflamm Bowel Dis; 2013 Jul; 19(4):761-6. PubMed ID: 23446337
    [Abstract] [Full Text] [Related]

  • 3. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P, Paul E, Huang C, Headon B, Sparrow MP.
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [Abstract] [Full Text] [Related]

  • 4. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A, Al-Taweel T, Sasson MS, Moza D, Strohl M, Kopylov U, Paradis-Surprenant L, Almaimani M, Bitton A, Afif W, Lakatos PL, Bessissow T.
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J, Sokol H, Bourrier A, Nion-Larmurier I, Wisniewski A, Landman C, Marteau P, Beaugerie L, Perez K, Seksik P.
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
    [Abstract] [Full Text] [Related]

  • 6. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
    Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L.
    Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
    [Abstract] [Full Text] [Related]

  • 7. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
    Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S.
    Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G, Brandimarte G.
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
    Kamal ME, Werida RH, Radwan MA, Askar SR, Omran GA, El-Mohamdy MA, Hagag RS.
    Inflammopharmacology; 2024 Oct; 32(5):3259-3269. PubMed ID: 38985232
    [Abstract] [Full Text] [Related]

  • 15. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, Ponsioen C, van Tuyl BA, Siersema PD, Fidder HH, Oldenburg B, Dutch Initiative on Crohn and Colitis (ICC).
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [Abstract] [Full Text] [Related]

  • 16. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B, Zingone F, D'Incà R, Rovigo L, Bertani L, Bodini G, Ghisa M, Gubbiotti A, Massimi D, Lorenzon G, Savarino EV.
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [Abstract] [Full Text] [Related]

  • 17. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B, Prka L.
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [Abstract] [Full Text] [Related]

  • 18. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
    Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, T Abreu M.
    Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.